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Background: Circulating white blood cells crucially contribute to maintenance and repair of solid organs. Therefore,
certain cell populations such as monocytes are attractive targets for use in molecular imaging and cell imaging, e.g.
after labelling with radionuclides, as well as for cell therapies. However, the preparation of monocytes may require
freezing and thawing to preserve cells for timely and standardised applications. Additional modifications of these
cells such as radioisotope labelling are necessary prior to their application in vivo. We therefore tested the
hypothesis whether cryopreservation of freshly isolated circulating human monocytes affects their functional
phenotype or their suitability for radionuclide labelling.
Results: CD14+CD16− monocytes were isolated from human peripheral blood. They were either directly used for
cellular assays and labelling or frozen down using cryoprotectants. In the latter case, cells were thawed prior to
further use and analysed for survival, chemotactic responses to various growth factors and adhesion on endothelial
cells. In addition, both fresh and cryopreserved monocytes were labelled with radiotracers followed by assessment
of survival and chemotactic responses. In all functional assays performed, cryopreserved monocytes did not
significantly differ from freshly isolated monocytes with regard to their functionality. Cryopreservation did not affect
cell survival. There was no effect on the chemotactic response of monocytes towards different growth factors.
Likewise, adhesion properties remained unchanged following cryopreservation. Moreover, the labelling efficiency
was similar for freshly isolated and cryopreserved monocytes. Labelling did not negatively affect monocyte survival
and function.
Conclusions: Our data indicate that cryopreservation of freshly isolated human primary monocytes is feasible and
does not negatively affect their functionality when used for labelling and functional assessment.
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Monocytes play an important role in inflammation and
in host defence as they participate in both innate and
adaptive immune responses. They are circulating mono-
nuclear phagocyte-like cells which are derived from a
common myeloid precursor in the bone marrow [1].
Although they do not proliferate outside the bone mar-
row, monocytes circulate for several days in the blood
stream to peripheral tissues where they patrol blood ves-
sels until they enter tissues and differentiate or until they
die [2–4]. In addition, undifferentiated monocytes can
reside in the subcapsular red pulp of the spleen in a
much higher concentration than in the circulation [5].
Monocyte recruitment and infiltration into tissues are
modulated by proinflammatory as well as metabolic
stimuli. Upon tissue infiltration, monocytes can further
differentiate irreversibly into tissue macrophages and/or
dendritic cells following stimulation by different factors
or induced by inflammation [4, 6].
Peripheral blood monocytes represent 5–10 % of the
human leukocytes in the peripheral blood. They show
morphological heterogeneity and can be categorised in
different subclasses depending on the expression of
CD14, which is part of the lipopolysaccharide (LPS)
receptor, and CD16, also known as the FcγRII receptor
[7, 8]. Human monocytes were classified into classical
CD14++CD16− (85–90 % of monocytes) and non-
classical CD14+CD16++ monocytes (10–15 % of the total
monocytes). As a third subset, the intermediate CD14+
+CD16+ monocytes was characterised [9]. Monocytes
play crucial roles in the clearance of bacteria, viruses
and toxic substances and in the eradication of apoptotic
and necrotic cells. In addition, monocytes participate in
the regulation of angiogenesis and arteriogenesis as well
as tissue repair following injury [10].
However, increased accumulation of monocytes ap-
pears in inflammatory diseases such as rheumatoid
arthritis, atherosclerosis, diabetes, hypertension, myo-
cardial infarction and other cardiovascular diseases
or cancer [7, 11, 12]. Thus, the ability of monocytes
to mobilise and migrate to the sites of inflammation,
angiogenesis/arteriogenesis and tissue repair is of
great importance. Moreover, monocytes are the in-
flammatory cell type dominating the infarcted myo-
cardium as they play an important role in heart
repair as well [10, 13]. Moreover, monocytes may
represent a therapeutic target after acute myocardial
infarction since increased accumulation of monocytes
lead to increased inflammation in the infarcted hearts
[10, 13]. So far, no data is available for human
monocyte mobility and accumulation following myo-
cardial infarction although different studies have fo-
cused on the characterisation of mouse monocyte
mobility [13].Chemotaxis, i.e. directed migration, is a crucial as-
pect of monocyte function. Several studies have
shown that CD14++CD16− monocytes from patients
with cardiovascular risk factors, such as diabetes mel-
litus, hypertension, smoking or hypercholesterolemia,
show a chemotactic defect towards vascular endothelial
growth factor-A (VEGF-A) and monocyte chemoattract-
ant protein-1 (MCP-1) ligands [14–20]. However, it re-
mains unknown how their chemotactic responses are
affected in vivo and whether this has an effect on the de-
velopment of cardiovascular diseases, arteriogenesis and
cardiovascular healing.
Monocytes are attractive targets for use in molecular
and cellular imaging as well as for cell therapy due to
their important role in vascular repair and cardiovascu-
lar diseases. Cellular imaging of monocytes will allow
their detection in the myocardium and their localization
within the infarct zone, the border zone or the remote
myocardium. In addition, cellular imaging would answer
the question whether the phenotype of circulating
monocytes in the blood stream correlates with the
phenotype of monocytes in the atherosclerotic lesions or
in the infarcted myocardium. Thus, techniques for track-
ing and localising human monocytes in vivo would be of
major importance. Targeted imaging approaches require
time-consuming modification of these cells prior to their
application in vivo and imaging for a prolonged time
(hours or more). The process of harvesting human cells
from patients with acute myocardial infarction, analysis
of cell function, radiolabelling of monocyte subfractions,
administration of cells into mice and finally performing
imaging with either planar and tomographic (single-pho-
ton emission computed tomography (SPECT)) scintig-
raphy or positron emission tomography (PET) is a long
process. As a consequence, imaging must be performed
outside office hours (i.e. in the late evening or during
the night) under suboptimal working conditions (e.g.
due to lack of imaging personnel). Therefore, intermedi-
ate freezing of the cells would be very beneficial for
timely and standardised application. We therefore tested
the hypothesis whether freezing and thawing, i.e. cryo-
preservation of circulating human monocytes affects the
functional phenotype of these cells or their suitability for
radioactive labelling.
Methods
Monocyte isolation from peripheral human blood
Monocytes were isolated from fresh human blood
leukocyte reduction chamber of platelet apheresis sets
enriched with white blood cells and platelets from
healthy subjects recruited by the blood bank of the
University Hospital Münster. The study was approved
by the scientific and ethics committee of the University
of Münster and conforms to the principles of the
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was obtained from all subjects. Mononuclear cells
(MNCs) were obtained from the blood by density
centrifugation using Leucosep® tubes (50 ml, with fil-
ter, Greiner) and the density gradient media Histopa-
que® 1077 (Sigma) separation solution. “MACS
Monocyte Isolation Kit II” (Miltenyi) was used for
isolation of CD14++CD16− monocyte subpopulation.
Following manufacturer’s instructions, non-monocytes
were magnetically labelled using a cocktail of biotin-
conjugated antibodies and anti-biotin MicroBeads. De-
pletion of these magnetically labelled cells was done
through magnetic separation. Isolated monocytes were
counted using CASY technology and washed once
with serum-free RPMI-1640 medium before used for
adhesion assay.Cryopreservation and subsequent thawing of human
monocytes
Monocytes were frozen for future use by suspending
10 × 106 cells/ml in ice cold freezing medium CTS®
Synth-a-Freeze® Medium (Gibco). One-millilitre aliquots
were dispensed to Biofreeze vials (Stratagene). The cells
were transferred to a cryofreezing container (Mr. Frosty,
Nalgene) and placed in a −80 °C freezer. On the follow-
ing day, the vials were transferred to liquid nitrogen and
stored there for a duration of 2 days up to 4 weeks be-
fore use. The cells were thawed quickly in a 37 °C water
bath and transferred into ten volumes of pre-warmed
RPMI medium supplemented with 10 % fetal bovine
serum (FBS). Trypan blue exclusion indicated that the
cells were >95 % viable just after thawing.Monocyte chemotaxis assays
Chemotaxis was analysed as previously described [21].
Briefly, freshly isolated human monocytes or cryopre-
served monocytes were resuspended in medium at a
concentration of 0.5 × 106 cells/ml. Subsequently, mono-
cytes were placed to the upper wells of a chemotactic
chamber (Neuroprobe) and migrated towards chemotac-
tic growth factors which were added to the lower wells
of the chamber. Upper and lower wells were separated
by a polycarbonate membrane (pore size 5 μm, Milli-
pore). The cells were allowed to migrate for 90 min in a
humidified incubator (5 % CO2) at 37 °C. Adherent cells
on polycarbonate membrane were fixed for 10 min using
absolute ethanol and stained with Giemsa dye. The non-
migrated cells from the upper side of the membrane
were scraped off gently with a cotton bud. Migrated cells
were quantified by counting cells in five high-power
fields (20× primary magnification) of four different wells
per condition.Human umbilical vein endothelial cells
Human umbilical vein endothelial cells (HUVECs) were
isolated from anonymized donors according to the
Declaration of Helsinki and approved by the ethics
boards of the University of Münster (2009-537-f-S).
HUVECs were cultivated as described before [22] on
gelatin (1 % in phosphate buffer saline (PBS)) coated
T25 and T75 flasks in M199 (containing 20 % FBS,
0.675 % bovine pituitary extract (BPE), 0.125 % heparin
and 1.25 % penicillin/streptomycin).
Adhesion assays
The ability of human monocytes to bind to HUVECs
was measured using previously reported methods [23].
Endothelial cells cultured in 48-well dishes were either
left unstimulated or stimulated for 4 h with 10 ng/ml
human tumour necrosis factor α (hTNFα) in M199
medium containing 1 % FBS at 37 °C. Human primary
monocytes were labelled with 4 pg/ml calcein (Invitro-
gen) at 37 °C for 15 min. Cells were washed once to re-
move excess of calcein and resuspended in RPMI
medium at a concentration of 2 × 105 cells/ml. Prior to
the adhesion assay, HUVECs were rinsed three times,
and 1 × 105 labelled monocytes per well were added.
After 20 min, unbound monocytes were removed and
the cells were washed three times with 1× PBS to re-
move non-adherent monocytes. Pictures were taken in
the middle of each well using a 5× objective, light at
490 nm with a Leica Microsystems DMI 3000B micro-
scope, a shutter Leica Microsystems EL6000 and image
software LAS V3.7. The number of cells was analysed by
ImageJ 1.45s (NIH) with the particle analysis plug-in.
Cell viability
Cells were seeded in a 96-well plate at a density of
100,000 cells per well in RPMI medium. Cell density was
determined every day using the CellTiter 96® AQueous
cell proliferation assay (MTS, Promega) according to the
manufacturer’s instructions. Briefly, 20 μl of reagent was
added to the test wells and incubated at 37 °C for 1 h in
5 % CO2. Optical density was measured at 490 nm by
spectrophotometric analysis and viability was calculated
as sample optical density divided by control optical
density. As a negative control, 150 μl of RPMI medium
and 20 μl MTS were used. In addition, the cells were
stained with trypan blue and evaluated using light mi-
croscopy. The viability observed was always more than
80 %. All assays were performed in triplicates.
Labelling of monocytes with 99mTc-HMPAO
99mTechnetium-hexamethylpropyleneamineoxime
(99mTc-HMPAO) was prepared using the stabilised
Ceretec cobalt labelling kit (GE Healthcare, Buchler
GmbH & Co. KG, Braunschweig, Germany) according to
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monocytes (7 × 106/sample) were resuspended in 100 μl
of 0.9 % NaCl. Per sample, 150 MBq of 99mTc-HMPAO
was added and cells were incubated at room
temperature for 20 min. Cells were spun down at
1100 rpm for 10 min and subsequently washed once
with 1× PBS. Radioactivity was measured using an ISO-
MED dose calibrator (MED Nuklearmedizin-Technik
Dresden GmbH, Dresden, Germany). Labelling efficiency
(LE) was estimated using the following formula: LE
= [C / (C +W)] × 100, where C is activity associated with
the cells and W is activity associated with the wash.
Reagents
Recombinant human vascular endothelial growth factor-
A (VEGF-A) and placenta growth factor-1 (PlGF-1) were
obtained from RELIATech GmbH (Braunschweig,
Germany). Recombinant human transforming growth
factor β1 (TGFβ1) and monocyte chemotactic protein-1
(MCP-1) were obtained from Peprotech GmBH (Ham-
burg, Germany). RPMI 1640 medium was purchased
from Invitrogen (Karlsruhe; Germany) and fetal calf
serum (FCS) from Biochrom AG (Berlin, Germany). Cell
Titer 96® non-radioactive cell proliferation assay was
purchased from Promega (Madison, WI, USA). Histopa-
que separation solution was obtained from Sigma-
Aldrich (Saint Louis, MO, USA).
Statistical analysis
Results are expressed as mean ± SEM using GraphPad
Prism (Version 5). To estimate the level of significance,
a one-way ANOVA non-parametric Kruskal-Wallis test
for unpaired samples with Dunn’s post test or the
Mann-Whitney test were used. A probability (p) value of
<0.05 was considered statistically significant. All calcula-
tions were performed using SPSS version 22 (*p < 0.05,
**p < 0.01, ***p < 0.001).
Results
Effects of cryopreservation on mononuclear cell viability
First, we characterised the effects of cryopreservation on
the recovery of cryopreserved CD14++CD16− monocytes.
As shown in Fig. 1a, cryopreservation resulted in 27.8 ±
12 % loss of monocytes after thawing. The viability of
both fresh and cryopreserved cells was tested using a
trypan blue exclusion assay. As shown in Fig. 1b, cell
cryopreservation had no statistically significant effect on
the ratio between alive and dead cells at 24 h; however,
the difference reaches statistical significance after 48 h
both for freshly isolated and cryopreserved cells. Never-
theless, considering that the cryopreserved cells will be
labelled and administrated immediately after thawing for
live cell imaging shortly after injection into the recipient,the small reduction in number of living cells at 48 h post
thawing may not affect the imaging results.
We further analysed the effects of cryopreservation on
survival of human monocytes using the MTS CellTiter
96 AQueous One Solution cell proliferation assay. The
data suggest that cryopreservation for short (2–4 days)
or longer periods of time (4–5 weeks) did not affect sur-
vival of CD14++CD16− monocytes (Fig. 1c–e). Neverthe-
less, there is a slight increase in proliferation/survival of
monocytes at 24 h. The MTS compound is processed by
cells into a coloured formazan product that is soluble in
tissue culture medium. This conversion is presumably
accomplished by NADPH or NADH produced by de-
hydrogenase enzymes in metabolically active cells. Thus,
the small increase in the survival at 24 h may reflect in-
creased metabolic activity of the cells at 24 h post isola-
tion (freshly isolated monocytes) and 24 h after thawing
(cryopreserved monocytes) and does not relate with
monocyte proliferation.
Chemotactic responses of fresh versus cryopreserved
human monocytes
One important aspect of monocyte function is chemo-
taxis, i.e. directed migration to sites of inflammation,
neoangiogenesis or collateral growth, i.e. arteriogenesis.
The effects of cryopreservation on mononuclear cell mi-
gration was analysed by comparing the migratory re-
sponses of freshly isolated and cryopreserved monocytes
to various concentrations of the growth factors PlGF-1,
VEGF-A, TGFβ1 and MCP-1 (Fig. 2). The results (n =
20) demonstrate that both fresh and cryopreserved
monocytes show significant migratory responses towards
the different chemoattractants (Fig. 2a–d). Although
there is a small reduction (5–15 %) of the chemotactic
responses in cryopreserved monocytes, there is no sig-
nificant difference (p > 0.05) when compared to freshly
isolated monocytes (one-way ANOVA Kruskal-Wallis
test with Dunn’s post test).
Cryopreservation does not affect monocyte adherence to
endothelial cells
An important aspect of monocyte function is their ad-
herence to the endothelium, which in turn is the initial
step of monocyte recruitment to inflammatory sites,
followed by transmigration through the endothelium.
Therefore, we analysed the effect of cryopreservation on
monocyte adhesion to HUVECs. Adhesion of cells on
unstimulated endothelial cells was set as 100 %. Our re-
sults (n = 6) suggest that both freshly isolated (100 and
202 %) as well as cryopreserved monocytes (100 and
232.2 %) adhere to both non-activated and TNFα-
activated HUVECs in a similar fashion (Fig. 3) and that
there are no significant differences (p > 0.05) in their
adhesion.
Fig. 1 Effects of cryopreservation on viability of CD14++CD16− monocytes. a Recovery of cryopreserved human monocytes after thawing.
b Freshly isolated and cryopreserved cells were analysed for their survival using a trypan blue exclusion method. Relative ratios of the alive-to-dead
freshly isolated and cryopreserved monocytes were calculated. c–e Freshly isolated and cryopreserved cells were analysed with the MTS viability assay
at 0 h, 24 h after isolation or thawing, 2–4 weeks (n = 7) or 4–5 weeks (n = 10) after cryopreservation. Statistics: Kruskal-Wallis test with Dunn’s post test,
p value: *p < 0.05
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their labelling with the radiopharmaceutical 99mTc-HMPAO
or their cellular function
Since monocytes are putative targets for use in molecular
and cellular imaging, there is an urgent need for the devel-
opment of novel approaches (e.g. the establishment of spe-
cific protocols) to study mononuclear cell trafficking in vivo.Fig. 2 Effects of cryopreservation on chemotaxis of CD14++CD16− monocy
for their chemotactic responses towards different concentrations of growth
Boyden chamber chemotaxis assay (n = 20). Statistics: Kruskal-Wallis test witWe sought to study whether labelling of human monocytes
with radiopharmaceuticals for cell tracking in vivo is efficient
and whether labelling does affect their function. Experi-
ments were performed both for fresh unfrozen cells and for
cryopreserved cells. We have chosen the radiopharmaceuti-
cal 99mTc-HMPAO which is established for cell labelling and
suitable for planar and tomographic scintigraphy.te. a–d Freshly isolated and cryopreserved monocytes were analysed
factors including PlGF1, VEGF-A, TGFβ and MCP-1 using a modified
h Dunn’s post test, p value: ***p < 0.001
Fig. 3 Effect of cryopreservation of CD14++CD16− monocytes on adhesion to endothelial cells. a Freshly isolated and cryopreserved primary
monocytes were allowed to adhere on TNFα stimulated or unstimulated HUVECs. b The number of adherent cells was quantified (n = 6).
Statistics: Kruskal-Wallis test with Dunn’s post test, p value: ***p < 0.001
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99mTc-HMPAO resulted in labelling efficiency (LE) of
50.6 % (Fig. 4a). Labelling did not affect cell survival of
mononuclear cells as measured by the MTS cell survival
assay (n = 12, p > 0.05; Fig. 4b). Moreover, we analysed the
effects of 99mTc-HMPAO labelling on chemotactic re-
sponses. Basal migration of cells was set as 100 %. Migra-
tion towards VEGF-A and MCP-1 was consistent for both
labelled (117.5 and 174.27 %) and non-labelled monocytes
(123.4 and 185.4 %). No significant difference to un-
labelled cells could be detected (n = 12, p > 0.05; Fig. 4b).Fig. 4 Effects of cryopreservation on monocyte 99mTc-HMPAO labelling
were radiolabelled with 150 MBq 99mTc-HMPAO and analysed a for the
at 0 and 24 h after labelling and c for their migratory responses towar
chamber chemotaxis assay (n = 12). Statistics: Kruskal-Wallis test with Du
*p < 0.05; **p < 0.01; ***p < 0.001These results suggest that 99mTc-HMPAO labelling of pri-
mary human monocytes does not strongly interfere with
mononuclear cell viability and function.
Next, we studied the effects of cryopreservation on
monocyte labelling. Cryopreserved human CD14++CD16
− monocytes were labelled with 99mTc-HMPAO. Label-
ling of cryopreserved monocytes with HMPAO resulted
in a LE of 33.8 % (Fig. 4a). The difference of LE of fresh
and cryopreserved cells did not reach statistical signifi-
cance (n = 12, p > 0.05). 99mTc-HMPAO labelling did not
affect viability of cryopreserved mononuclear cells asand functionality. Freshly isolated and cryopreserved monocytes
efficiency of labelling, b for their survival using the MTS viability
ds VEGF-A (10 ng/ml) and MCP-1 (10 ng/ml) in a modified Boyden
nn’s post test, or the Mann-Whitney test was performed, p value:
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preserved labelled monocytes migrated efficiently to-
wards VEGF-A and MCP-1 and showed no significant
differences to unlabelled cells (Fig. 4c). These results
suggest that 99mTc-HMPAO labelling of cryopreserved
monocytes is as efficient as using freshly isolated mono-
cytes as labelling does not interfere with mononuclear
cell viability and function.
Discussion
Monocytes are attractive targets for use in cellular imaging
and for cell therapies as they play important roles in vascu-
lar repair and cardiovascular diseases. Both concepts re-
quire the ex vivo modification of cells prior to their
application in vivo. An intermediate freezing step may be
very beneficial to preserve cells for timely and standardised
application in order to optimise imaging experiments, e.g.
by avoiding imaging during off hours. For this, we sought
to investigate whether freezing and thawing of circulating
primary human monocytes affects the functional phenotype
of these cells and their suitability for radioactive labelling.
Our results suggest that cryopreservation of primary hu-
man CD14++CD16− monocytes does not interfere with
their survival as cryopreserved monocytes showed no defi-
cits in viability compared to freshly isolated monocytes. In
addition, our data show that the chemotactic responses of
cryopreserved monocytes towards different concentrations
of various growth factors are not negatively affected. Our
results suggest that cryopreserved monocytes retain their
ability to adhere to quiescent as well as activated endothe-
lium to similar levels as freshly isolated monocytes do.
Thus, primary monocytes can be isolated safely at any
time point, cryopreserved and stored for later use. More-
over, cryopreserved monocytes can be used for functional
testing such as endothelial adhesion assays and migration
assays along with isolates from other types of patients and
controls. Our results are in line with previous studies
which demonstrated that cryopreservation of human
monocytes does not affect viability, migration or differen-
tiation of monocytes into macrophages and dendritic cells,
IL6 secretion and cryopreserved monocyte could be used
efficiently in the monocyte activation test (MAT) [24, 25].
Our study has shown that cryopreservation of human
CD14++CD16− monocytes does not interfere with their
suitability for radiolabelling with 99mTc-HMPAO for
subsequent cell imaging. In fresh and cryopreserved
monocytes, labelling with 150 MBq 99mTc-HMPAO does
not affect mononuclear cell survival or their chemotactic
responses The labelling efficiency was lower in our study
for cryopreserved cells when compared to fresh cells, al-
beit not significantly. Cellular accumulation and reten-
tion of 99mTc-HMPAO relies on (1) the conversion of
the lipophilic 99mTc-HMPAO complex into a hydrophilic
complex. and 2) on the redox state of cells or thereaction of 99mTc-HMPAO with sulphydryl reagents like
glutathione inside the cell [26–28]. It has been suggested
that intracellular conversion of the hydrophobic Tc-
HMPAO to a species which is incapable of rapid back
diffusion involves interaction of 99mTc-HMPAO with
glutathione. [29]. It was shown that cryopreservation of
human and rat hepatocytes and human sperm results in
reduced glutathione content and glutathione-
conjugating capacity [30, 31]. Based on these studies we
could suggest that the slightly reduced labelling effi-
ciency of cryopreserved human monocytes is due to re-
duced glutathione levels.
The establishment of a protocol to cryopreserve and
revitalise primary human monocytes, which can be radi-
olabelled while retaining their viability and their func-
tionality, represents a major advancement for both
cellular imaging and cell therapy. This will allow the sys-
tematic usage of these cells as well as the comparison of
cells from different patients. It has previously been
shown that monocytes from either diabetes mellitus or
hypercholesterolemic patients exhibit defective chemo-
tactic responses to individual growth factors ex vivo in-
cluding VEGF-A or MCP-1 [14–17, 20, 32]. It remains
unclear whether reduced growth factor induced chemo-
tactic responses are relevant for mononuclear cell func-
tion in vivo and to the development of atherosclerosis
and/or to effective vascular healing in patients.
Based on the ability of monocytes and macrophages to
phagocytose, several approaches have been developed
for their targeted imaging in vivo. For example, different
types of nanoparticles labelled with isotopes such as
fluorine-18 [33] and copper-64 [34] or ultra-small super-
paramagnetic iron oxide (USPIO) nanoparticles were
used to image monocytes/macrophages with positron
emission tomography (PET) and magnetic resonance im-
aging (MRI), respectively [35]. In addition, the standard
PET tracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG),
a glucose analogue, is taken up in vivo after intravenous
injection by cells with a high metabolic rate such as
mononuclear cells. It has been used for imaging inflam-
mation of atherosclerotic plaques in coronary arteries
[36–38]. Nevertheless, [18F]FDG is not specific for leu-
kocytes in the atherosclerotic plaque. The same tracer
could be used for in vitro labelling of inflammatory cells
before injection for tracking mononuclear cells in vivo.
However, [18F]FDG leakage out of these labelled cells
would interfere with imaging specificity. It is thus of
great importance to develop methods which will allow
us to track and study primary human monocytes from
different patients in vivo. The establishment of a method
to cryopreserve and later efficiently label human mono-
cytes ex vivo will allow us to study their localisation
in vivo as well as their function and contribution to
vascular healing in preclinical mouse models of
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more insights into the mononuclear cell dysfunction and
how this translates into their role in vivo as well as their
contribution to the development of vascular diseases.
Monocytes play an important role in myocardial in-
farction healing. However, they may have damaging ef-
fects on the myocardium in the early and late
reperfusion period as well [10, 13, 39]. Therefore, im-
aging approaches to detect increased and sustained in-
flammation post MI will be of great importance for
estimating the effect of monocytes on myocardial dam-
age and repair. Moreover, ex vivo labelled monocytes
can be used to localise them in vivo within the infarcted
myocardium and the border zone. This may reveal hints
to appreciate their potential contribution to post-infarct
healing in preclinical mouse models as well as in con-
secutive clinical studies for in vivo trafficking of mono-
nuclear cells in the human post-infarcted heart.
Conclusions
Taken together, our work demonstrates that freshly iso-
lated and then cryopreserved monocytes, subsequently
thawed and labelled with the radiotracer 99mTc-HMPAO,
retain all functional properties that have been tested so
far. Therefore, monocyte cryopreservation as docu-
mented in our approach is feasible and will benefit stud-
ies on monocytes for cellular imaging and cell therapy.
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